Effect of omission of surgery on survival in patients aged 80 years and older with early-stage hormone receptor-positive breast cancer

A. Z. de Boer1,2, N. A. de Glas2, P. J. Marang-van de Mheen3, O. M. Dekkers4, S. Siesling5,6, L. de Munck5, K. M. de Ligt5,6, G. J. Lieflers1, J. E. A. Portielje2 and E. Bastiaannet1,2

Departments of 1Surgery, 2Medical Oncology, 3Medical Decision-Making and 4Clinical Epidemiology, Leiden University Medical Centre, Leiden, 5Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, and 6Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands

Correspondence to: Ms A. Z. de Boer, Department of Surgery, Leiden University Medical Centre, Location J10-71, Postzone K6-R, PO Box 9600, 2300 RC Leiden, the Netherlands (e-mail: a.z.de_boer@lumc.nl)

Background: Surgery is increasingly being omitted in older patients with operable breast cancer in the Netherlands. Although omission of surgery can be considered in frail older patients, it may lead to inferior outcomes in non-frail patients. Therefore, the aim of this study was to evaluate the effect of omission of surgery on relative and overall survival in older patients with operable breast cancer.

Methods: Patients aged 80 years or older diagnosed with stage I–II hormone receptor-positive breast cancer between 2003 and 2009 were selected from the Netherlands Cancer Registry. An instrumental variable approach was applied to minimize confounding, using hospital variation in rate of primary surgery. Relative and overall survival was compared between patients treated in hospitals with different rates of surgery.

Results: Overall, 6464 patients were included. Relative survival was lower for patients treated in hospitals with lower compared with higher surgical rates (90.2 versus 92.4 per cent respectively after 5 years; 71.6 versus 88.2 per cent after 10 years). The relative excess risk for patients treated in hospitals with lower surgical rates was 2.00 (95 per cent c.i. 1.17 to 3.40). Overall survival rates were also lower among patients treated in hospitals with lower compared with higher surgical rates (48.3 versus 51.3 per cent after 5 years; 15.0 versus 19.7 per cent after 10 years respectively; adjusted hazard ratio 1.07, 95 per cent c.i. 1.00 to 1.14).

Conclusion: Omission of surgery is associated with worse relative and overall survival in patients aged 80 years or more with stage I–II hormone receptor-positive breast cancer. Future research should focus on the effect on quality of life and physical functioning.

Paper accepted 2 February 2020
Published online 7 April 2020 in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.11568

Introduction

The number of older patients with breast cancer is increasing owing to ageing of Western populations. This age group differs in terms of co-morbidity, physical and cognitive functioning, and demands a personalized approach to cancer treatment. Less extensive treatments are often given when co-morbidity or a limited life expectancy is assumed to interfere with treatment benefit. Selection criteria for treatments are, however, poorly defined in guidelines as evidence from RCTs is lacking. Consequently, treatment variation is seen across countries, regions and hospitals. Previous studies have shown that the percentage of older patients who do not undergo primary surgical treatment has increased over the past decade in the Netherlands. Most of these patients receive primary endocrine therapy instead of surgery. The assumption is that, with primary endocrine therapy, disruption of daily life may be minimized and risks of surgery can be avoided. After an uncertain length of time, disease progression will, however, occur and a change of treatment is required. Endocrine therapy can also have many side-effects affecting quality of life, especially in older patients.

International recommendations state that primary endocrine therapy should be considered only in patients with a life expectancy of 2–3 years and who are unfit for, or refuse, surgery. Although RCTs comparing...
surgical treatment and tamoxifen monotherapy reported high rates of local progression in patients treated with tamoxifen alone, none showed a survival difference before 3 years\textsuperscript{12,13}. The applicability of data from these studies, undertaken in the 1980s, to current practice is questionable. Hormone receptor testing is now mandatory, and aromatase inhibitors have been shown to be superior to tamoxifen in both (neo)adjuvant and metastatic settings\textsuperscript{14–16}. Furthermore, multiple lines of endocrine agents are available\textsuperscript{13,17,18}. In addition, advances in anaesthetic techniques have made breast surgery a safe procedure\textsuperscript{17}, even in the very old\textsuperscript{19}. Moreover, previous RCTs included only older patients who were considered fit enough to undergo surgery, which limits the generalizability of the results to the general population of older patients with breast cancer\textsuperscript{12}.

Population-based data may provide more insight into the effect of omission of surgery in the older patient population in current practice. Comparison of patients treated with and without surgery in observational data is, however, susceptible to confounding by indication. Although statistical techniques may adjust for measured confounders, such as age and co-morbidity, residual confounding by unmeasured factors related to frailty is likely to be present. The variation in omission of surgery among hospitals provides the opportunity to use the instrumental variable approach, an alternative method to minimize confounding. The aim of this study was to evaluate the effect of omission of surgery on relative and overall survival by comparing the outcomes of patients treated in hospitals with different rates of primary surgery.

**Methods**

Patients aged 80 years or older diagnosed with stage I–II hormone receptor-positive breast cancer between 2003 and 2009 were selected from the Netherlands Cancer Registry (NCR) and included in this study. The NCR is a database on cancer diagnosis and treatment hosted by the Netherlands Comprehensive Cancer Organization (IKNL). It receives reports of diagnosed malignancies from the nationwide network and registry of histopathology and cytopathology in the Netherlands (PALGA), which are confirmed and completed by the national hospital discharge databank. The interval 2003–2009 was chosen to allow sufficiently long follow-up.

Trained data managers collect data on diagnosis, staging and treatment from medical records using international coding rules. Breast cancer stage is defined according to the sixth edition of the TNM classification of malignant tumours\textsuperscript{20}. Clinical tumour or node category was used when pathological stage was unknown. Oestrogen receptor and progesterone receptor status was considered positive if at least 10 per cent positive nuclear staining of tumour cells was demonstrated. Information on co-morbidity was collected for this study, but only for patients diagnosed in 2007–2009 for logistic reasons. For patients diagnosed between 2003 and 2006, data on co-morbidity were available only for those diagnosed in one of the nine regions in the Netherlands, as this is the only region that regularly collects such information. Missing co-morbidity data for the other regions were imputed (see below). Vital status was available until 31 January 2017 through linkage of NCR data with the Municipal Personal Records database.

**Hospital variation**

In clinical practice, the decision to omit surgery is based on disease characteristics, age, co-morbidity, and other aspects of general health and frailty, such as physical, cognitive and social functioning. As these latter factors are generally not measured or well recorded in observational databases, statistical techniques such as multivariable analysis or propensity score matching cannot fully adjust for them, leaving residual confounding. Previous studies\textsuperscript{21–23} have demonstrated that residual confounding can lead to implausible results. To minimize confounding, an instrumental variable approach was used. Under certain assumptions, this method can adjust for unmeasured confounding. Variation in the percentage of patients undergoing primary surgery across hospitals (the instrument) was used, and outcomes of patients treated in hospitals with different rates of primary surgery were compared\textsuperscript{22}. Hospital was used as instrument as rates of primary surgery varied substantially across hospitals, and no major differences in case mix between hospitals were expected as all hospitals in the Netherlands provide breast cancer care and older patients are assumed to go to the hospital nearest their home. Therefore, groups of hospitals are similar with respect to patients’ prognosis and general health, and potential differences in outcomes can be attributed to the difference in surgery rates. Hospitals that contributed fewer than ten patients were excluded.

Three groups were defined by dividing 117 hospitals based on rates of primary surgery while ensuring equal numbers of patients in each group: hospitals with higher rates (range 75.9–100 per cent), moderate rates (63.2–75.8 per cent) and lower rates (37.6–63.1 per cent). Those treated in these hospitals are referred to as patients treated in hospitals with higher, moderate and lower rates of surgery respectively. The rate of surgery is defined as the rate of primary surgery. To evaluate the effect of using hospital variation to minimize confounding, patient characteristics of the three groups were compared.
Statistical analysis

Multiple imputation by chained equation was performed to account for missing values of grade, human epidermal growth factor receptor (HER) 2 status and co-morbidity. Missing values for these variables were assumed to be missing at random after examination of patterns. Imputation models were applied including all variables as predictors. Results were based on the pooled results of 25 imputed sets according to Rubin’s rules. Pearson’s χ² tests were used to assess differences in patient characteristics between groups.

In observational data, the time between diagnosis and the start of treatment is ‘immortal time’ as a patient had to survive this period to start the treatment. As the time to treatment was immortal for patients who underwent surgery in this study, a landmark approach was used to avoid immortal time bias. Hence, follow-up time started 60 days after diagnosis. Patients who died before this landmark were excluded from the survival analysis. Follow-up ended at the date of death or last follow-up visit.

As older patients with breast cancer often die from causes other than those related to breast cancer, the primary outcome was relative survival. Relative survival was used as proxy for breast cancer-specific survival (BCSS) as cause of death is not available in the NCR. Moreover, ascertaining cause of death in older patients is susceptible to misclassification bias. Relative survival is calculated by dividing the observed survival in a patient population by the expected survival in the general population matched by age, sex and year of diagnosis. Hence, relative survival takes into account the patient population’s background mortality and in the present study expresses the excess risk of death owing to breast cancer. Relative survival estimates cancer-specific survival under the condition that the general population’s mortality is representative of the background mortality in the patient population. In other words, the prevalence of co-morbid diseases should be similar in the patient population and the general population. Relative survival is considered a reliable outcome in older patients with breast cancer as it has been demonstrated that the prevalence of co-morbid diseases is indeed comparable among patients with breast cancer and those without cancer. To compare relative survival, relative excess risks with 95 per cent confidence intervals were calculated using generalized linear Poisson models. Patients treated in hospitals with higher rates of surgery were used as reference group.

Kaplan–Meier estimates of overall survival were calculated. To compare overall survival, hazard ratios (HRs) with 95 per cent confidence intervals were calculated using Cox proportional hazard models. Patients treated in hospitals with higher rates of surgery were used as reference group. In addition, to explore different effects of omission of surgery in patients with and without co-morbidity, a stratified analysis was performed in groups with a Charlson Co-morbidity Index (CCI) score of 0 or at least 1. As a statistically significant age difference across the groups remained despite applying the instrumental variable approach to reduce confounding, a multivariable analysis including age was undertaken. The proportionality assumption was tested by plotting the scaled Schoenfeld residuals. No violation of the assumption was found.

All statistical tests were two-sided and P < 0.05 was considered statistically significant. Statistical analysis was done with SPSS® version 23.0 (IBM, Armonk, New York, USA) and Stata® version 12.1 (StataCorp, College Station, Texas, USA).

Results

A total of 6464 older patients with stage I–II hormone receptor-positive breast cancer were included. Overall, 4465 patients (69.1 per cent) underwent surgery and 1999 (30.9 per cent) did not. There were differences in characteristics between the two groups (Table 1). Patients who

| Table 1 Characteristics of patients who were treated with or without primary surgery |
|----------------------------------|----------|--------|--------|
|                                  | Surgery  | No surgery | P*     |
|                                  | (n = 4465) | (n = 1999) |        |
| Age (years)                      |          |          | < 0.001 |
| 80–84                            | 2870 (64.3) | 615 (30.8) |        |
| 85–89                            | 1324 (29.7) | 829 (41.5) |        |
| ≥ 90                             | 271 (6.1)  | 555 (27.8) |        |
| CCI score                        |          |          | < 0.001 |
| 0                                | 980 (21.9; 54.3) | 510 (25.5; 41.7) |        |
| 1                                | 468 (10.5; 26.7) | 386 (19.3; 31.6) |        |
| ≥ 2                              | 323 (7.2; 19.0)  | 321 (16.1; 26.8) |        |
| Unknown                          | 2694 (60.3) | 782 (39.1)  |        |
| TNM stage                        |          |          | 0.866   |
| I                                | 1458 (32.7) | 657 (32.9)  |        |
| II                               | 3007 (67.4) | 1342 (67.1) |        |
| Tumour grade                     |          |          | 0.159   |
| 1                                | 1098 (24.6; 26.2) | 101 (5.1; 31.5) |        |
| 2                                | 2306 (51.6; 55.2) | 180 (9.0; 51.8) |        |
| 3                                | 784 (17.6; 18.6)  | 61 (3.1; 16.7)  |        |
| Unknown                          | 277 (6.2)  | 1657 (82.9) |        |
| HER2 status                      |          |          | 0.689   |
| Positive                         | 217 (4.9; 7.4)  | 79 (4.0; 7.8)  |        |
| Negative                         | 2864 (64.1; 92.6) | 977 (48.9; 92.2) |        |
| Unknown                          | 1384 (31.0)  | 943 (47.2)  |        |

Values in parentheses are percentages including missing data; percentages after multiple imputation. CCI, Charlson Co-morbidity Index; HER2, human epidermal growth factor receptor 2. *Pearson’s χ² test.
Table 2 Characteristics of patients who were treated at hospitals with higher, moderate or lower rates of primary surgery

| Treatment                      | Higher rates (n = 2159) | Moderate rates (n = 2158) | Lower rates (n = 2147) | P*  |
|--------------------------------|-------------------------|---------------------------|------------------------|-----|
| Surgery                        | 1784 (82.6)             | 1505 (69.7)               | 1176 (54.8)            |     |
| Primary endocrine treatment    | 329 (15.2)              | 615 (28.5)                | 937 (43.6)             |     |
| No treatment                   | 46 (2.1)                | 38 (1.8)                  | 34 (1.6)               |     |
| Age (years)                    |                         |                           |                        | 0.003|
| 80–84                          | 1216 (56.3)             | 1163 (53.9)               | 1106 (51.5)            |     |
| 85–89                          | 705 (32.7)              | 722 (33.5)                | 726 (33.8)             |     |
| ≥ 90                           | 238 (11.0)              | 273 (12.7)                | 315 (14.7)             |     |
| CCI score                      |                         |                           |                        | 0.985|
| 0                              | 448 (20.6; 50.5)        | 488 (22.6; 50.2)          | 554 (25.8; 50.6)       |     |
| 1                              | 260 (12.0; 27.9)        | 293 (13.8; 29.0)          | 301 (14.0; 27.7)       |     |
| ≥ 2                            | 209 (9.7; 21.6)         | 198 (9.2; 20.8)           | 237 (11.0; 21.6)       |     |
| Unknown                        | 1242 (57.5)             | 1179 (54.6)               | 1055 (49.1)            |     |
| TNM stage                      |                         |                           |                        | 0.215|
| I                              | 680 (31.5)              | 705 (32.7)                | 730 (34.0)             |     |
| II                             | 1479 (68.5)             | 1453 (67.3)               | 1417 (66.0)            |     |
| Tumour grade                   |                         |                           |                        | 0.511|
| 1                              | 475 (22.0; 28.1)        | 389 (18.0; 27.2)          | 335 (15.6; 28.3)       |     |
| 2                              | 946 (43.8; 54.1)        | 878 (40.7; 55.9)          | 662 (30.8; 52.4)       |     |
| 3                              | 318 (14.7; 17.8)        | 257 (11.9; 16.8)          | 270 (12.6; 19.3)       |     |
| Unknown                        | 420 (19.5)              | 634 (29.4)                | 880 (41.0)             |     |
| HER2 status                    |                         |                           |                        | 0.554|
| Positive                       | 96 (4.4; 7.7)           | 104 (4.8; 7.8)            | 96 (4.5; 7.1)          |     |
| Negative                       | 1252 (58.9; 92.3)       | 1246 (57.2; 92.0)         | 1343 (62.6; 92.9)      |     |
| Unknown                        | 811 (37.6)              | 808 (37.4)                | 708 (33.0)             |     |
| RT after BCS                   |                         |                           |                        | 0.066|
| Yes                            | 251 (70.3)              | 310 (71.1)                | 234 (77.7)             |     |
| No                             | 106 (29.7)              | 126 (28.9)                | 67 (22.3)              |     |
| RT after mastectomy            |                         |                           |                        | 0.298|
| Yes                            | 67 (4.7)                | 64 (6.0)                  | 51 (5.8)               |     |
| No                             | 1360 (95.3)             | 1005 (94.0)               | 824 (94.2)             |     |
| Adjuvant endocrine therapy     |                         |                           |                        | 0.627|
| Yes                            | 1015 (56.9)             | 875 (58.1)                | 663 (56.4)             |     |
| No                             | 769 (43.1)              | 630 (41.9)                | 513 (43.6)             |     |
| Adjuvant chemotherapy          |                         |                           |                        | –    |
| Yes                            | 7 (0.3)                 | 1 (<0.1)                  | 1 (<0.1)               |     |
| No                             | 2152 (99.7)             | 2157 (>99.9)              | 2146 (>99.9)           |     |

Values in parentheses are percentages including missing data; percentages after multiple imputation. CCI, Charlson Co-morbidity Index; HER2, human epidermal growth factor receptor 2; RT, radiotherapy; BCS, breast-conserving surgery. *Pearson’s χ² test.

did not have surgery were more often older; 69.2 per cent of these patients were aged 85 years or older compared with 35.7 per cent of patients who had surgery (P < 0.001). Among patients who did not undergo surgery, 58.3 per cent had a CCI score of 1 or more, compared to 45.7 per cent of those who had surgery (P < 0.001). No differences in stage, grade or HER2 status were observed after multiple imputation (Table 1). Of the patients who did not have surgery, 94.1 per cent received primary endocrine treatment.

Rates of surgery were on average 82.6, 69.7 and 54.8 per cent in the hospitals with higher, moderate and lower rates of surgery respectively. Furthermore, 15.2, 28.5 and 43.6 per cent received primary endocrine treatment, whereas 2.1, 1.8 and 1.6 per cent received no treatment (Table 2; Fig. S1, supporting information). Patients treated in hospitals with lower rates of surgery were more often older than patients treated in hospitals with moderate and higher rates (48.5 per cent aged 85 years or more versus 46.1 and
Fig. 1 Cumulative relative survival and overall survival of patients treated in hospitals with different rates of primary surgery

(a) Relative survival and (b) overall survival.

Table 3 Relative survival and relative excess risk for patients treated in hospitals with different rates of primary surgery

|                  | Surgically treated patients (%) | Relative survival (%) | Relative excess risk* | P        |
|------------------|---------------------------------|-----------------------|----------------------|----------|
|                  | 5 years                         | 10 years              |                      |          |
| Higher rates     | 82.6                            | 92.4 (88.5, 96.2)     | 88.2 (80.4, 96.3)    | 1.00 (0.96, 1.09) |
| Moderate rates   | 69.7                            | 91.1 (87.2, 95.0)     | 79.0 (71.4, 86.8)    | 1.29 (0.70, 2.39) |
| Lower rates      | 54.8                            | 90.2 (86.2, 94.2)     | 71.6 (64.1, 79.4)    | 2.00 (1.17, 3.40) |

Values in parentheses are 95 per cent confidence intervals. *Model included all available follow-up.

Table 4 Cox proportional hazards analysis for overall survival of patients treated in hospitals with different rates of primary surgery stratified by co-morbidity

|                  | Surgically treated patients (%) | Overall survival (%) | Hazard ratio* | P        | Age-adjusted hazard ratio* | P        |
|------------------|---------------------------------|----------------------|---------------|----------|----------------------------|----------|
|                  | 5 years                         | 10 years             |               |          |                            |          |
| All patients     | 0.003                           | 0.135                |               |          |                            |          |
| Higher rates     | 82.6                            | 51.3 (49.2, 53.4)    | 19.8 (18.0, 21.6) | 1.00 (reference) | 1.00 (reference) |          |
| Moderate rates   | 69.7                            | 49.9 (47.8, 52.0)    | 17.2 (15.5, 18.9) | 1.04 (0.98, 1.12) | 1.03 (0.96, 1.09) |          |
| Lower rates      | 54.8                            | 48.3 (46.2, 50.4)    | 15.0 (13.4, 16.7) | 1.12 (1.05, 1.20) | 1.07 (1.00, 1.14) |          |
| CCI score 0      | 0.060                           | 0.646                |               |          |                            |          |
| Higher rates     | 88.2                            | 60.4 (59.8, 61.0)    | 25.9 (25.3, 26.4) | 1.00 (reference) | 1.00 (reference) |          |
| Moderate rates   | 74.4                            | 57.9 (57.3, 58.5)    | 22.4 (21.9, 22.9) | 1.06 (0.96, 1.18) | 1.02 (0.91, 1.13) |          |
| Lower rates      | 60.2                            | 56.5 (55.9, 57.1)    | 20.1 (19.6, 20.6) | 1.13 (1.03, 1.25) | 1.05 (0.95, 1.16) |          |
| CCI score ≥ 1    | 0.143                           | 0.323                |               |          |                            |          |
| Higher rates     | 76.7                            | 40.1 (39.7, 40.5)    | 11.5 (11.2, 11.8) | 1.00 (reference) | 1.00 (reference) |          |
| Moderate rates   | 64.7                            | 40.7 (40.2, 41.1)    | 11.2 (10.9, 11.5) | 1.02 (0.99, 1.14) | 1.02 (0.92, 1.15) |          |
| Lower rates      | 48.8                            | 39.1 (38.7, 39.5)    | 10.3 (10.0, 10.6) | 1.10 (1.00, 1.22) | 1.08 (0.98, 1.20) |          |

Values in parentheses are 95 per cent confidence intervals. *Model included all available follow-up. CCI, Charlson Co-morbidity Index.
43.7 per cent respectively; *P* = 0.003). No other differences were observed across the groups.

Of the 6464 patients, 6363 were included in the survival analysis as six patients were lost to follow-up and 95 died in the first 60 days after diagnosis. Relative survival is shown in Fig. 1a. Relative survival was lower for patients treated in hospitals with lower compared with higher rates of surgery (90.2 versus 92.4 per cent after 5 years; 71.6 versus 88.2 per cent after 10 years) (Table 3). Compared with the reference group of patients treated in hospitals with higher rates of surgery, the relative excess risk of death was 2.00 (95 per cent c.i. 1.17 to 3.40) for patients treated at hospitals with lower rates (Table 3). Of note, the relative survival curves are overlapping for the first 5 years (Fig. 1a).

Overall survival rates were also lower for patients treated in hospitals with lower compared with higher rates of surgery (48.3 versus 51.3 per cent after 5 years; 15.0 versus 19.8 per cent after 10 years) (Fig. 1b and Table 4). Compared with the reference group of patients treated in hospitals with higher rates of surgery, the adjusted HR for death was 1.07 (95 per cent c.i. 1.00 to 1.14) for patients treated at hospitals with lower rates (Table 4). Stratified by co-morbidity, the adjusted HR for death among patients treated in hospitals with lower compared with higher rates of surgery was 1.05 (0.95 to 1.16) in patients with a CCI score of 0, and 1.08 (0.98 to 1.20) among those with a CCI score of at least 1.

**Discussion**

This study showed that omission of surgery had no effect during the first 5 years of follow-up, but was associated with worse relative and overall survival after 5 years in patients aged 80 years or older with stage I–II hormone receptor-positive breast cancer.

These findings support the recommendation of international guidelines that primary endocrine treatment is an alternative for patients with a life expectancy of 2–3 years, although, based on the data presented here, it could be argued that primary endocrine treatment is justified in patients with a life expectancy up to 5 years. In a systematic review,12 of six RCTs comparing surgery and tamoxifen monotherapy, only one trial13 demonstrated a survival advantage in favour of surgery. Findings of the present study are in line with results from that trial, although with the finding of similar survival during the first 3 years compared with 5 years in the present study. The emergence of aromatase inhibitors might have improved the efficacy of primary endocrine treatment and contributed to this difference. This is substantiated by the findings of a cohort study,18 in which 616 patients received primary endocrine treatment during the years when aromatase inhibitors were introduced; although 69.3 per cent of the patients received tamoxifen as first-line agent, the study demonstrated a median time to progression of 49 (range 4–132) months.18

It is important to recognize that the early trials included only patients aged 70 years or more who were considered fit for surgery, whereas all patients aged 80 years or older in the Netherlands, including frail patients, were included in the present population-based cohort study. Because of this, the burden of mortality from non-breast cancer-related causes was considerably higher here, which could explain why the effect on survival was seen after a longer period.

There are no randomized data available comparing surgery and aromatase inhibitor monotherapy. The ESTEem (Endocrine +/- Surgical Therapy for Elderly women with Mammary cancer) trial was initiated to compare anastrozole with and without surgery, but unfortunately had to close owing to poor accrual. Patient preference for a specific treatment may have contributed to the disappointing accrual. Furthermore, in clinical practice, omission of surgery is generally considered in frail older patients and the participation of this patient group in RCTs is often poor.

Several observational studies have compared outcomes of patients treated with primary surgery or primary endocrine treatment. The majority demonstrated superior BCSS and overall survival in patients who had primary surgery32,33. Only one study18 did not report a difference in 5-year BCSS between patients who had surgery versus primary endocrine treatment among those aged 80 years or more. Residual confounding owing to differences in general health and frailty between patients who had primary surgery and those who received primary endocrine treatment is usually not measured in observational databases, which makes direct comparisons at risk of bias.

In the present study, patients treated with and without primary surgery were not compared directly; instead, outcomes were compared in groups of patients treated in hospitals with different rates of primary surgery. As the measured patient and tumour characteristics were similar across the groups, the amount of residual confounding by unmeasured factors was reduced. An instrumental variable approach, however, requires further assumptions, such as similar quality of hospital care.34. With a difference of 27·8 per cent in omission of surgery between the hospitals with higher and lower rates of surgery, both relative survival and overall survival were worse for patients treated in the hospitals with lower rates. As expected, overall survival rates are lower than relative survival rates owing to the high population mortality in this age group. Consequently, the impact of omission of surgery on relative survival translates into
a smaller impact on overall survival, and for some patients with high competing mortality risks this absolute benefit is likely small enough to justify omission of surgery. On the other hand, the present data suggest that, if rates of surgery in patients aged 80 years and older were to increase, survival after 5 years may improve.

Given the overlapping survival curves, the present data may suggest that omission of surgery can be considered in patients with a life expectancy below 5 years. Yet, even in patients with limited life expectancy, there are reasons for being reluctant to offer primary endocrine treatment as an alternative to surgery. Endocrine therapy often has side-effects, such as hot flushes, joint pain and fatigue, which can impair activities of daily living and quality of life. Furthermore, in the adjuvant setting, non-persistence with endocrine therapy has been demonstrated to increase with older age. As patients with favourable tumour characteristics (grade 1 up to 2 cm in size; grade 2 up to 1 cm) do not receive adjuvant endocrine treatment in the Netherlands, such patients can be spared endocrine therapy completely after primary surgery.

Another disadvantage of primary endocrine treatment is that it is only effective for a limited period, after which a switch of treatment is needed. Although different lines of endocrine treatment are available, surgery may eventually be necessary. Furthermore, whereas primary endocrine treatment requires long-term regular hospital visits to evaluate disease progression, few hospital visits are required after surgery. The main advantage of primary endocrine treatment over surgery is that the risks and inconvenience of surgery can be avoided. Breast surgery, however, is associated with low morbidity rates, and age itself is not a risk factor for postoperative complications. The inconvenience of primary endocrine treatment may persist for a long time, whereas the inconvenience of having surgery is generally temporary. Accurately estimating life expectancy is not straightforward. In 2018, the life expectancy of a Dutch woman aged 70 years was 17.3 years, and for a woman aged 80 years was 9.9 years. Certain co-morbidities can decrease life expectancy, but impaired cognition, malnutrition and dependency in activities of daily living are also important predictors. As these factors may not always be recognized, a geriatric assessment is advisable. The present findings underline that estimating life expectancy is important for optimal treatment decisions, but unfortunately this is often difficult for patients aged over 80 years.

Strengths of this study were that hospital variation was used to minimize confounding by indication as much as possible, and relative survival was calculated, which takes into account mortality from other causes. All consecutive patients in a large, nationwide cohort were included with detailed information on tumour characteristics and co-morbidity. Limitations of this study were related to the data and methodology. Information on treatments was limited to the first year after diagnosis, and it is therefore unknown how many patients eventually had surgery after primary endocrine treatment. No information on specific endocrine agents and successive lines of endocrine therapy was available. Inherent to following the instrumental variable approach using hospital variation in rates of primary surgery, only the impact of a difference in rate of surgery of 27-8 per cent could be assessed, which reduced the statistical power. Although this was sufficient to demonstrate a survival difference in the primary analysis, the findings for the stratified analysis suggest a lack of power. Although confounding by unmeasured factors can theoretically be avoided using the instrumental variable approach, an instrument that meets all of the required assumptions is not always available in clinical data. There was a small age difference across the groups in the present study. Although age was adjusted for in multivariable analysis, residual confounding could not be ruled out completely.

Future research is needed to evaluate the side-effects of primary endocrine treatment using aromatase inhibitors, compliance and treatment switches, and to compare quality of life and physical functioning of patients treated with surgery or primary endocrine therapy.

Acknowledgements

The authors thank the IKNL for data collection. Disclosure: The authors declare no conflict of interest.

References

1. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 2016; 66: 31–42.
2. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 2017; 67: 439–448.
3. Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012; 13: e148–e160.
4. Derks MGM, Bastiaannet E, Kiderlen M, Hilling DF, Boelens PG, Walsh PM et al.; EURECCA Breast Cancer Group. Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group. Br J Cancer 2018; 119: 121–129.
5 Morrow ES, Dolan RD, Doughty J, Stallard S, Lannigan A, Romics L. Variation in the management of elderly patients in two neighboring breast units is due to preferences and attitudes of health professionals. *Breast Cancer* 2019; **11**: 179–188.

6 Morgan J, Richards P, Ward S, Francis M, Lawrence G, Collins K et al. Case-mix analysis and variation in rates of non-surgical treatment of older women with operable breast cancer. *Br J Surg* 2015; **102**: 1056–1063.

7 Hamaker ME, Bastiaannet E, Evers D, van de Water W, Smorenburg CH, Maartense E et al. Omission of surgery in elderly patients with early stage breast cancer. *Eur J Cancer* 2013; **49**: 545–552.

8 de Glas NA, Jonker JM, Bastiaannet E, de Craen AJM, van de Velde CJH, Siesling S et al. Impact of omission of surgery on survival of older patients with breast cancer. *Br J Surg* 2014; **101**: 1397–1404.

9 Wink CJ, Woensdregt K, Nieuwenhuijzen GAP, van der Sangen MJC, Hutschemaekers S, Roukema JA et al. Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. *Ann Surg Oncol* 2012; **19**: 1185–1191.

10 Sitlinger A, Shelby RA, Van Denburg AN, White H, Edmond SN, Marcom PK et al. Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer. *J Geriatr Oncol* 2019; **10**: 317–321.

11 Wagner LI, Zhao F, Goss PE, Chapman JW, Shepherd LE, Whelan TJ et al. Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). *Breast Cancer Res Treat* 2018; **169**: 537–548.

12 Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review. *Br J Cancer* 2007; **96**: 1025–1029.

13 Fennessy M, Bates T, Stallard S, Lannigan A, Romics L. Late follow-up of a randomized trial of surgery versus tamoxifen alone in women aged over 70 years with operable breast cancer. *Br J Surg* 2004; **91**: 699–704.

14 Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E et al.; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial. *J Clin Oncol* 2019; **37**: 105–114.

15 Eiermann W, Paepke S, Appelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J et al.; Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. *Ann Oncol* 2001; **12**: 1527–1532.

16 Mouridsen H, Gershanyovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. *J Clin Oncol* 2003; **21**: 2101–2109.

17 Fentiman IS, Christiaens M-R, Paridaens R, Van Geel A, Rutgers E, Berner J et al.; EORTC. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. *Eur J Cancer* 2003; **39**: 309–316.

18 Syed BM, Al-Khyatt W, Johnston SJ, Wong DWM, Winterbottom L, Kennedy H et al. Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre. *Br J Cancer* 2011; **104**: 1393–1400.

19 StatLine. Health Expectancy; Since 1981. [https://opendata.cbs.nl/statline/#/CBS/en/dataset/71950eng/table?ts=1564667559737 ](https://opendata.cbs.nl/statline/#/CBS/en/dataset/71950eng/table?ts=1564667559737) [accessed 1 August 2019].

20 Greene FL, Page DL, Fleming I, Fritz A, Balch C, Haller DG et al. *AJCC Cancer Staging Manual* (6th edn). Springer: New York, 2002.

21 Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS. Limits of observational data in determining outcomes from cancer therapy. *Cancer* 2008; **112**: 2456–2466.

22 Bosco JLF, Silliman RA, Thwin SS, Geiger AM, Buist DSM, Prout MN et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. *J Clin Epidemiol* 2010; **63**: 64–74.

23 van Maaren MC, le Cessie S, Strobbe LJA, Groothuis-Oudshoorn CGM, Poortmans PMP, Siesling S. Different statistical techniques dealing with confounding in observational research: measuring the effect of breast-conserving therapy and mastectomy on survival. *J Cancer Res Clin Oncol* 2019; **145**: 1485–1493.

24 Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ* 2009; **338**: b2393.

25 Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. *BMJ Med Res Methodol* 2009; **9**: 57.

26 Agarwal P, Moshier E, Ru M, Ohri N, Ennis R, Rosenzweig K et al. Immortal time bias in observational studies of time-to-event outcomes: assessing effects of postmastectomy radiation therapy using the national cancer database. *Cancer Control* 2018; **25**: 1073274818789355.

27 Park HS, Gross CP, Makarov DV, Yu JB. Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy. *Int J Radiat Oncol Biol Phys* 2012; **83**: 1365–1373.

28 Schaffar R, Rapiti E, Rachet B, Woods L. Accuracy of cause of death data routinely recorded in a population-based cancer registry: impact on cause-specific survival and
validation using the Geneva Cancer Registry. *BMC Cancer* 2013; 13: 609.

29 Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. *Natl Cancer Inst Monogr* 1961; 6: 101–121.

30 Danese MD, O’Malley C, Lindquist K, Gleeson M, Griffiths RI. An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer. *Ann Oncol* 2012; 23: 1756–1765.

31 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987; 40: 373–383.

32 Morgan JL, Reed MW, Wyld L. Primary endocrine therapy as a treatment for older women with operable breast cancer – a comparison of randomised controlled trial and cohort study findings. *Eur J Surg Oncol* 2014; 40: 676–684.

33 Ward SE, Richards PD, Morgan JL, Holmes GR, Broggio JW, Collins K et al. Omission of surgery in older women with early breast cancer has an adverse impact on breast cancer-specific survival. *Br J Surg* 2018; 105: 1454–1463.

34 Dekkers OM. On causation in therapeutic research: observational studies, randomised experiments and instrumental variable analysis. *Prev Med* 2011; 53: 239–241.

35 van de Water W, Bastiaannet E, Hille ETM, Kranenbarg EMMK, Putter H, Seynaeve CM et al. Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis. *Oncologist* 2012; 17: 55–63.

36 Ten Wolde B, Kuiper M, de Wilt JHW, Strobbe LJA. Postoperative complications after breast cancer surgery are not related to age. *Ann Surg Oncol* 2017; 24: 1861–1867.

37 de Glas NA, Kiderlen M, Bastiaannet E, de Craen AJM, van de Water W, van de Velde CJH et al. Postoperative complications and survival of elderly breast cancer patients: a FOCUS study analysis. *Breast Cancer Res Treat* 2013; 138: 561–569.

38 Thomas R, Pieri A, Cain H. A systematic review of generic and breast cancer specific life expectancy models in the elderly. *Eur J Surg Oncol* 2017; 43: 1816–1827.

39 Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. *Lancet Oncol* 2018; 19: e305–e316.